Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer

ABSTRACT: Interventions: Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine X2,000mg/m2, p.o.(day1-14) to be repeated every 3 weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2619370 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR